Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
暂无分享,去创建一个
Andrew J. Bannister | S. Robson | S. Knapp | O. Fedorov | C. Bountra | S. Müller | R. Prinjha | T. Kouzarides | Kevin Lee | P. Jeffrey | P. Brennan | N. L. La Thangue | P. Filippakopoulos | S. Picaud | M. Philpott | K. Che | A. Tumber | D. Daniels | M. Urh | N. Parr | Sarah Martin | D. Lugo | D. Hay | A. Thanasopoulou | Simon Taylor | S. Velichko | K. Jones | C. Yapp | Umesh Kumar | M. Vecellio | Octovia P. Monteiro | J. Schwaller | J. Meier | K. Leonards | A. O’Mahony | Heidi Olzscha | C. Wells
[1] L. Wodicka,et al. Abstract 5387: Dual kinase/bromodomain inhibitors for rationally designed polypharmacology , 2014 .
[2] Jessica E. Bolden,et al. Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition , 2014, Cell reports.
[3] A. Gingras,et al. Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching , 2014, Epigenetics & Chromatin.
[4] S. Knapp,et al. Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.
[5] Zhoulei Li,et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma , 2014, Proceedings of the National Academy of Sciences.
[6] Junwei Shi,et al. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.
[7] S. Knapp,et al. Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.
[8] S. Kaufmann,et al. Differential gene expression of activating Fcγ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[9] E. Ortega,et al. Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation , 2013, Nature Structural &Molecular Biology.
[10] S. Knapp,et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. , 2013, Cancer research.
[11] Li-li Wang,et al. A Histone Acetyltransferase p300 Inhibitor C646 Induces Cell Cycle Arrest and Apoptosis Selectively in AML1-ETO-Positive AML Cells , 2013, PloS one.
[12] K. Cermakova,et al. Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75) , 2013, Leukemia.
[13] Nathan Brown,et al. Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites , 2012, Journal of medicinal chemistry.
[14] S. Knapp,et al. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family , 2012, Bioorganic & medicinal chemistry.
[15] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[16] S. Robson,et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.
[17] B. Göttgens,et al. The Transcriptional Coactivator Cbp Regulates Self-Renewal and Differentiation in Adult Hematopoietic Stem Cells , 2011, Molecular and Cellular Biology.
[18] S. Knapp,et al. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. , 2011, Molecular bioSystems.
[19] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[20] S. Knapp,et al. 3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands , 2011, Journal of medicinal chemistry.
[21] A. Melnick,et al. The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation , 2011, Science.
[22] Jihong Chen,et al. Life and death of transcriptional co-activator p300 , 2011, Epigenetics.
[23] W. Parson,et al. Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines , 2011, Molecular Cancer Therapeutics.
[24] Ming-Ming Zhou,et al. A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. , 2011, Chemistry & biology.
[25] C. Rice,et al. Suppression of inflammation by a synthetic histone mimic , 2010, Nature.
[26] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[27] H. Kimura,et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains , 2010, The EMBO journal.
[28] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[29] Tina N. Davis,et al. Systematic in vivo structure-function analysis of p300 in hematopoiesis. , 2009, Blood.
[30] G. Smyth,et al. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.
[31] S. Agrawal,et al. Mechanism of p300 specific histone acetyltransferase inhibition by small molecules. , 2009, Journal of medicinal chemistry.
[32] A. Brasier,et al. The STAT3 NH2-terminal Domain Stabilizes Enhanceosome Assembly by Interacting with the p300 Bromodomain* , 2008, Journal of Biological Chemistry.
[33] I. Kitabayashi,et al. Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis , 2008, Cancer science.
[34] Zhenghe Wang,et al. Differential binding modes of the bromodomains of CREB-binding protein (CBP) and p300 with acetylated MyoD. , 2008, Biochemical and biophysical research communications.
[35] J. Rehg,et al. Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells. , 2006, Blood.
[36] Wei-Guo Zhu,et al. Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21Waf1/Cip1 , 2006, Molecular and Cellular Biology.
[37] T. Golub,et al. Conditional MLL‐CBP targets GMP and models therapy‐related myeloproliferative disease , 2005, The EMBO journal.
[38] J. Rowley,et al. Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16) , 2004, Genes, chromosomes & cancer.
[39] C. Caldas,et al. p300/CBP and cancer , 2004, Oncogene.
[40] W. Taylor,et al. Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. , 2004, Cancer cell.
[41] Roberto Sanchez,et al. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. , 2004, Molecular cell.
[42] J. Tschopp,et al. BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF , 2001, Science.
[43] Changchun Du,et al. Chromatin‐related properties of CBP fused to MLL generate a myelodysplastic‐like syndrome that evolves into myeloid leukemia , 2000, The EMBO journal.
[44] D. Livingston,et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. , 2000, Genes & development.
[45] M. Cleary,et al. CREB Binding Protein Interacts with Nucleoporin-Specific FG Repeats That Activate Transcription and Mediate NUP98-HOXA9 Oncogenicity , 1999, Molecular and Cellular Biology.
[46] David Newsome,et al. Gene Dosage–Dependent Embryonic Development and Proliferation Defects in Mice Lacking the Transcriptional Integrator p300 , 1998, Cell.
[47] F. Behm,et al. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. , 1997, Blood.
[48] Diwakar,et al. SUPPLEMENTARY INFORMATION for Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes , 2014 .
[49] L. Cooper,et al. Mammalian two-hybrid assays for studies of interaction of p300 with transcription factors. , 2013, Methods in molecular biology.
[50] Stefan Knapp,et al. Kinase inhibitor selectivity profiling using differential scanning fluorimetry. , 2012, Methods in molecular biology.